ALNY
Alnylam Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$266.11
+0.61%Aug 28, 2026, 09:23 UTC
AstraZeneca announced on Friday that its Phase 3 clinical trial for an experimental silencer drug in ATTR-CM patients failed to show additional benefit over existing stabilizer therapy, impacting its partnership with Ionis Pharmaceuticals and the broader market.
Aug 24, 2026, 12:33 UTC
Alnylam Pharmaceuticals announced it will present new clinical and real-world data across its ATTR and hypertension programs at the ESC Congress 2026 in Munich, Germany, from August 28-31, 2026.
Source:Jul 30, 2026, 14:06 UTC
Alnylam Pharmaceuticals reported second-quarter 2026 global net product revenue of approximately $1.2 billion, up 74% from a year earlier.
Jun 25, 2026, 13:00 UTC
Komodo Health expanded its strategic partnership with Alnylam Pharmaceuticals to scale the Marmot AI platform across Alnylam's enterprise functions.
Source:Jun 23, 2026, 19:53 UTC
GENESIS Pharma expanded its commercial partnership with Alnylam Pharmaceuticals to include Denmark, Finland, Norway, and Sweden, covering 17 markets for RNAi therapies targeting cardiomyopathy and rare genetic diseases.
Source:Jun 10, 2026, 11:47 UTC
GENESIS Pharma expanded its strategic commercial partnership with Alnylam Pharmaceuticals for RNAi therapeutics to the Nordic region.
Source:Jun 3, 2026, 20:45 UTC
Alnylam Pharmaceuticals and Inceptive Nucleics formed a strategic AI collaboration to accelerate the discovery of RNAi therapeutics, valued at up to $2 billion with $30 million upfront.